List of Piqray drug patents

Piqray is owned by Novartis.

Piqray contains Alpelisib.

Piqray has a total of 2 drug patents out of which 0 drug patents have expired.

Piqray was authorised for market use on 24 May, 2019.

Piqray is available in tablet;oral dosage forms.

Piqray can be used as in combination with fulvestrant for treatment of postmenopausal women, and men, with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer.

Drug patent challenges can be filed against Piqray from May, 2023.

The generics of Piqray are possible to be released after 28 September, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8476268 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Sep, 2029

(6 years from now)

US8227462 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Sep, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 24, 2024

Drugs and Companies using ALPELISIB ingredient

NCE-1 date: May, 2023

Market Authorisation Date: 24 May, 2019

Treatment: In combination with fulvestrant for treatment of postmenopausal women, and men, with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in